Ligand Pharmaceuticals | LGND - Assets


Ligand Pharmaceuticals reported $2.19B in Assets for its fiscal quarter ending in June of 2026.





Assets Change Date
Agenus USD 172.69M 13.76M Jun/2026
Amgen USD 95.64B 3.14B Jun/2026
Anika Therapeutics USD 183.47M 4.09M Jun/2026
Arrowhead Research USD 2.11B 156.25M Jun/2026
Baxter International USD 19.79B 55M Jun/2026
Bristol-Myers Squibb USD 87.63B 1.16B Jun/2026
Eli Lilly USD 142.28B 25.71B Jun/2026
Enanta Pharmaceuticals USD 329.5M 48.77M Dec/2025
Enviri Corporation USD 2.7B 4.56M Mar/2026
Gilead Sciences USD 49.36B 6.92B Jun/2026
GlaxoSmithKline GBP 61.74B 1.13B Jun/2026
Glaxosmithkline GBP 62.87B 19.47B Mar/2026
Heron Therapeutics USD 246.22M 9.66M Mar/2026
Insmed USD 2.1B 26.7M Jun/2026
Intrexon USD 73.16M 77.88M Jun/2024
Ionis Pharmaceuticals USD 2.99B 455.5M Jun/2026
Karyopharm Therapeutics USD 131.42M 23M Mar/2026
Ligand Pharmaceuticals USD 2.19B 653.77M Jun/2026
MacroGenics USD 217.87M 38.97M Mar/2026
Merck USD 129.8B 1.12B Jun/2026
Pacira USD 1.24B 35.44M Jun/2026
Pfizer USD 201.13B 6.49B Jun/2026
Rigel Pharmaceuticals USD 242.53M 35.8M Sep/2025
Sangamo BioSciences USD 97.56M 11.39M Jun/2025
Veracyte USD 1.49B 49.97M Jun/2026